Thankfully, organizations are experiencing a shortage in research subjects for Ebola trials in West Africa.
As a result of the decline in the number of Ebola cases, there may be a shortage of research subjects for fast-developing treatments. NPR suggests that approximately 27,000 participants are needed.
Vaccine trials, however, largely rely on healthy volunteers. As such, preventative vaccines for Ebola will move forward regardless of the spread of the disease.
"We're in a bit of a strange situation," says WHO's Martin Friede, who heads the group coordinating Ebola drug development. "On the one hand, the number of Ebola cases has really dropped dramatically. ... This is excellent for the countries involved," Friede says. "However, from a drug research and development perspective, this is not so good."